Combination therapies against HIV-1 infection: Exploring the concept of combining antiretroviral drug treatments with HIV-1 immune-based therapies in asymptomatic individuals

AIDS Patient Care and STDs

Volumn 10, Issue 6, 1996, Pages 357-361

  Ferre, Francois ^a   Moss, Ronald B ^a   Daigle, Anne E ^a   Trauger, Richard J ^a   Richieri, Steven P ^a   Jensen, Fred C ^a   Carlo, Dennis J ^a  

^a Orchestra Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; RANTES; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; IMMUNOTHERAPY; REVIEW; VIRUS RESISTANCE;

EID: 0030468554     PISSN: 08935068     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.1996.10.357     Document Type: Review

References (47)

1. Moss, R.B., Ferre, F., Levine, A., et al. Viral load, CD4 percentage and delayed-type hypersensitivity in subjects receiving the HIV-1 Immunogen and antiviral drug therapy. J Clin Immun 16:266-271, 1996.
2. Volberding, P.A., Lagakos, S.W., Koch, M.A., et al. Zidovudine in asymptomatic HIV infection - a controlled trial in persons with fewer than 500 CD4+ cells per cubic millimeter. N Engl J Med 322:941-949, 1990.
3. Volberding, P.A., Lagakos, S.W., Grimes, J.M., et al. The duration of zidovudine benefit in persons with asymptomatic HTV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 272:437-442, 1994.
4. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zi- dovudine in symptom-free HIV infection. Lancet 343:871-881, 1994.
5. Volberding, P.A., Lagakos, S.W., Grimes, J.M., et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 333:401-407, 1995.
6. Kinloch-de Loës, S., Hirschel, B.J., Hoen, B., et al. A controlled trial of zidovudine in primary HIV infection. N Engl J Med 333:408-413, 1995.
7. Ho, D.D. Time to hit HIV, early and hard. N Engl J Med 333:450-451, 1995.
8. Carpenter, C.C.J., Fischl, M.A., Hammer, S.M., et al. Antiretroviral therapy for HIV infection in 1996. JAMA 276:146-154, 1996.
9. Shafer, R.W., Merigan, T.C. New virologic tools for the design and analysis of clinical trials. J Inf Dis 171:1325-1328, 1995. Shafer, R.W., Merigan, T.C. HIV virology for clinical trial. ATDS 9:(suppl A), 1995.
10. Shafer, R.W., Merigan, T.C. New virologic tools for the design and analysis of clinical trials. J Inf Dis 171:1325-1328, 1995. Shafer, R.W., Merigan, T.C. HIV virology for clinical trial. ATDS 9:(suppl A), 1995.
11. Mitsuya, H., Yarchoan, R. Development of antiretroviral therapy for AIDS and related disorders. In Broder, S., Merigan T, Bolognesi, D., eds., Textbook of AIDS Medicine. Baltimore; Williams & Wilkins. 721-742, 1994.
12. Lewis, W., Dalakas, M.C. Mitochondrial toxicity of antiviral drugs. Nature Med 5:417-422, 1995.
13. Dalakas, M.C., Illa, I., Pezeshkpour, G., Laukaitis, J., Cohen, B., Griffin, J. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 322:1098-1105, 1990.
14. Danner, S., Carr, A., Leonard, J., et al. A shortterm study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 333:1528-1533, 1995.
15. Markowitz, M., Saag, M., Powderly, W., et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Eng J Med 333:1534-1539, 1995.
16. Condra, J. H., Schleif, W., Blahy, P.M., et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571, 1995.
17. Salk, J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 327:473-476, 1987.
18. Yarchoan, R., Mitsuya, H., Broder, S. Chal lenges in the therapy of HFV infection. Immunology Today 6:303-309, 1993.
19. Pakker, N.G., Roos, M.T.L., Jong de, M., et al. Analyses of T cell repopulation and restoration of T cell function during therapy with different antiretrovirais. XI International Conference on AIDS, Vancouver, British Columbia, July 7-12, 1996, Abstr. We.B.291.
20. Fahey, J.L., Schooley, R. Status of immunebased therapies in HIV infection and AIDS. Clin Exp Immunol 88:1-5, 1992.
21. Birx, D.L., Davis, C., Ruiz, N., et al. Results of a Phase II double-blinded, multicenter, placebo controlled HIV therapeutic vaccine trial. XI International Conference on AIDS, Vancouver, British Columbia, July 7-12, 1996, Abstr. Tu.A.275.
22. Kovacs, J.A., Baseler, M., Dewar, R.J., et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med 332:567-575, 1995.
23. -1. XI International Conference on AIDS, Vancouver, British Columbia, July 7-12, 1996, Abstr. We.B.292.
24. Dolan, M.J., Clerici, M., Blatt, S.P., et al. In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with HIV. J Inf Dis 172:79-87, 1995.
25. Trauger, R.J., Giermakowska, W.K., Ferre, F., et al. Cell-mediated immunity to HIV-1 in Walter Reed stages 1-6 individuals: correlation with virus burden. Immunology 78:611-615, 1993.
26. Blatt, S.P., Hendrix, C.W., Butzin, C.A., et al. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 119:177-184, 1993.
27. Birx, D.L., Brundage, J., Larson, K., et al. The prognostic utility of delayed-type hypersensitivity skin testing in the evaluation of HIV-infected patients. J AIDS 6:1248-1257, 1993.
28. Gordin, F.M., Hartigan, P.M., Klimas, N.G., et al. Delayed-type hypersensitivity skin tests are an independent predictor of HIV disease progression. J Inf Dis 169:893-897, 1994.
29. Turner, J.L., Trauger, R.J., Daigle, A.E., et al. HIV-1 immunogen induction of HTV-1-specific delayed-type hypersensitivity: results of a double-blind, adjuvant-controlled, dose-ranging trial. AIDS 8:1429-1435, 1994.
30. Salk, P., Salk, J. Cell-mediated immunologic memory in prevention and treatment of HIV disease. Res Immunol 145:629-633, 1994.
31. Levine, A., Groshen, S., Allen, J., et al. Initial studies on active immunization of HFV-infected subjects using a gp120-depleted HTV-1 Immunogen: long-term follow-up. J Acquir Immune Defic Syndr Hum Retro 11:351-364, 1996.
32. Moss, R.B., Giermakowska, W.K., Wallace, M., et al. Chemokines and cytokines in HIV-1-seropositive subjects receiving the HIV-1 Immunogen. Abstract #177, presented at the Annual Meeting of the Institute of Human Virology (published in J. of AIDS and Human Retrovirology), Baltimore, September 7-13, 1996.
33. Trauger, R.J., Ferre, F., Daigle, A.E., et al. Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) Immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Inf Dis 169:1256-1264, 1994.
34. Miedema, F., Klein, M. AIDS pathogenesis: A finite immune response to blame? Science 272:505, 1996.
35. Cocchi, F., DeVico, A.L., Garzino-Demo, A., et al. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8 + T cells. Science 270:1811-1815, 1995.
36. Alkhatib, G., Combadiere, C., Broder, C., et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophagetropic HVI-1. Science 272:1955-1958, 1996.
37. Deng, H., Liu, R., Ellmeier, W., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666, 1996.
38. Dragic, T., Litwin, V., Allaway, G.P., et al. HIV-1 entry in CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673, 1996.
39. Clerici, M., Landay, A.L., Kessler, H.A., et al. Reconstitution of long-term T helper cell function after zidovudine therapy in HIV-infected patients. J Inf Dis 166:723-730, 1992.
40. French, M.A.H., Cameron, P.U., Grimsley, G., et al. Correction of HIV-associated depression of delayed-type hypersensitivity (DTH) after zidovudine therapy: DTH, CD4+ T-cell numbers, and epidermal langerhans cell density are independent variables. Clin Immunol and Immunopath 55:86-96, 1990.
41. Kelleher, A., Carr, A., Zaunders, J., et al. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infec Dis 173:321-329, 1996.
42. Bevan, M.J., Braciale, T.J. Why can't cytotoxic T cells handle HIV? Proc Natl Acad Sci 92:5765-5767, 1995.
43. Bremermann, H.J. Mechanism of HIV persistence: Implications for vaccines and therapy. J AIDS Hum Retro 9:459-183, 1995.
44. Zinkernagel, R., Hengartner, H. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol Today 15:262, 1996.
45. Harrer, T., Harrer, E., Kalams, S., et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retro 12(7):585-592, 1996.
46. Wolinsky, S., Korber, B., Neumann, A., et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272:537, 1996.
47. Riviere, Y., McChesney, M., Porrot, F., et al. Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res Hum Retro 11(8):903-907, 1995.